SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017How to measure your success; globally and locally- Yvan Hutin, MD, PhDView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Setting the stage - Key challenges in elimination- Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Real-life experiences - Egypt- Imam Waked, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017WHO status report: Global response to the strategic framework- Yvan Hutin, MD, PhDView Slideset
GDPGiovanni Di PerriMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017One pill a day?: Integration novel delivery systems into routine care- Giovanni Di Perri, MD, PhDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Prospects of immunotherapy for treatment- Michael Lederman, MDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'AvinoView Slideset
MPMiłosz ParczewskiMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017Clinical case presentation- Miłosz Parczewski, MD, PhDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. PalichView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le HingratView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier DelelisView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Clinical case presentation- Christina Mussini, MDView Slideset
